ABSTRACT
OBJECTIVE: Calcitonin gene related peptide (CGRP), which has a vasodilator effect, is held responsible for neurogenic inflammation and vasodilatation of the cranial vessels in migraine pathophysiology. In this study, we investigated the association between alpha CGRP gene polymorphism (CALCA T-692C) and migraine. MATERIAL AND METHODS: One hundred and thirty-four female migraineurs and 96 healthy female cases were enrolled in the study. The patient group was further subdivided into migraine with and without aura groups. The CALCA T-692C gene polymorphism was identified using polymerase chain reaction (PCR) technique and restriction fragment length polymorphism (RFLP). RESULTS: The genotype and allele frequencies of CALCA T-692C gene polymorphism did not differ between the migraine and control groups. Between the migraine with and without aura subgroups, there was no difference. No association was seen between the CALCA T-692C gene polymorphisms and migraine attack severity and frequency. CONCLUSION: Our study did not show any association between CALCA T-692C gene polymorphism and migraine.
Subject(s)
Calcitonin Gene-Related Peptide/genetics , Genetic Predisposition to Disease/genetics , Migraine Disorders/genetics , Polymorphism, Single Nucleotide , Adult , Chi-Square Distribution , Female , Gene Frequency , Genetic Association Studies , Genotype , HumansABSTRACT
OBJECTIVES: To investigate the effects of strontium ranelate, raloxifene and misoprostol on bone mineral density (BMD) in ovariectomized rats to contribute to the individualization of the treatment of postmenopausal osteoporosis. STUDY DESIGN: Sixty sexually mature female Sprague-Dawley rats weighing 250 g were used. The 60 rats were divided into six groups of 10 rats each: SR, MISO, RAL, SHAM, DW and OVX. All except the SHAM rats were subjected to bilateral ovariectomy. Three days after surgery, rats were administered strontium ranelate (Protelos, 2 g, Servier, Istanbul), 1800 mg/kg/day; misoprostol (Cytotec, 200 mcg, Ali Raif, Istanbul), 200 mcg/kg/day; raloxifene (Evista, 60 mg, Lily and Company, Istanbul), 3 mg/kg/day and 1 cc of distilled water by gavage for 8 weeks. Bone mineral density measurements were then performed. RESULTS: The strontium ranelate (SR) group had significantly higher vertebral BMD than all other groups. Femoral density in the SR group was also significantly higher than in other groups and there was no difference between femoral density in the strontium ranelate and sham groups. CONCLUSIONS: Strontium ranelate, raloxifene and misoprostol can prevent bone loss in the vertebrae, whereas strontium ranelate can also prevent bone loss in the femur of ovariectomized rats. Strontium ranelate increases greater than raloxifene and misoprostol BMD in the vertebrae. CONDENSATION: Strontium ranelate may increase both vertebral and femur BMD in ovariectomized rats while raloxifene and misoprostol may only increase lumbar spine BMD.
Subject(s)
Bone Density Conservation Agents/pharmacology , Bone Density/drug effects , Misoprostol/pharmacology , Organometallic Compounds/pharmacology , Osteoporosis, Postmenopausal/prevention & control , Raloxifene Hydrochloride/pharmacology , Thiophenes/pharmacology , Animals , Female , Humans , Ovariectomy , Rats , Rats, Sprague-DawleyABSTRACT
OBJECTIVE: The aim of this study was to investigate, by using transvaginal ultrasonography, the possible effects on endometrial thickness of antihypertensive agents in asymptomatic postmenopausal women. DESIGN: A prospective study in an outpatient menopause clinic of a university hospital. We included 288 postmenopausal women in this study, and we compared three groups of postmenopausal women as follows: (1) normotensive postmenopausal women, (2) hypertensive women treated with an antihypertensive drug (beta-blocker, non-beta-blocker, or beta-blocker plus non-beta-blocker), and (3) untreated hypertensive women who had had hypertension for at least 1 year. Hypertensive women treated with a drug had been receiving treatment for 1 year. All women were interviewed and examined. Measurements of endometrial thickness were carried out by vaginal ultrasonography. RESULTS: Sixty-two women (22%) were normotensive, and 226 (78%) of 288 women were hypertensive. Of the 226 women, 122 (54%) were receiving an antihypertensive drug. The mean (+/- SD) endometrial thicknesses in groups A, B, and C were 4.5 (+/- 1.3), 5.4 (+/- 1.5), and 6.4 (+/- 1.7) mm, respectively. Significant difference was obtained among the groups (P = 0.004). CONCLUSIONS: Our data indicate that the mean endometrial thickness is significantly greater in asymptomatic, hypertensive women receiving antihypertensive drugs than among untreated hypertensive and normotensive women.
